Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort
Maria Giovanna Quaranta(Istituto Superiore di Sanità), Loreta A. Kondili(Istituto Superiore di Sanità), Luisa Cavalletto(University of Padua), Maria Mazzitelli(Agostino Gemelli University Polyclinic), Marco Massari(Azienda Sanitaria Unità Locale di Reggio Emilia), Luigina Ferrigno(Departamento de Epidemiología), Marco Cannizzaro(Ospedale Vincenzo Cervello), Diletta Laccabue(University of Parma), Martina Loi(University of Cagliari), Martina De Siena, Marzia Margotti(University of Bologna), Pasqualina De Leo(Ospedale San Paolo), Marcello Dallio(University of Campania "Luigi Vanvitelli"), Alessia Ciancio(Department of Medical Sciences), Alessia Giorgini(Università Cattolica del Sacro Cuore), Leonardo Baiocchi(Policlinico Tor Vergata), Xhimi Tata, Valentina Cossiga(University of Naples Federico II), Serena Rita Bruno(Ospedali Riuniti di Foggia), Giuseppina Brancaccio, Carmine Coppola, Franca D’Angelo(Istituto Superiore di Sanità)
Cited by 29
Related Papers
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection
|American Journal of Transplantation|2016|631
Hay fever and asthma in relation to markers of infection in the United States
|Journal of Allergy and Clinical Immunology|2002|303